Latest Industry News & Trends

Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.

Myopia News

11/15/2024
BreakingClinical TrialMyopia
Eyenovia Scraps Phase III Study of Low-Dose Atropine in Myopia After Endpoint Missed
Eyenovia Scraps Phase III Study of Low-Dose Atropine in Myopia After Endpoint Missed

Eyenovia reported Nov. 15 that it would scrap the Phase III CHAPERONE trial of low-dose atropine in pediatric myopia after an independent data review committee determined that the trial is not meet...

10/15/2024
AIDealsDiagnosticDigitalFundingMyopiaNewsletterPharmaPresbyopiaRetina
Orasis Leads Latest Ophthalmic Deals with $78 Million Financing
Orasis Leads Latest Ophthalmic Deals with $78 Million Financing

Orasis Pharmaceuticals led recent ophthalmic fundraising efforts with $78 million in Series D and structured capital to support the launch of Qlosi drops for presbyopia. Financing announced in the ...

9/19/2024
MeetingMyopiaNewsletter
Ophthalmologists Compare Myopia Interventions at WOC as Prevalence Soars
Ophthalmologists Compare Myopia  Interventions at WOC as Prevalence Soars

Myopia—especially progression of myopia—is getting increased attention from industry and physicians, as evidenced by the sheer number of studies published on the topic. Additionally, data showing h...

9/19/2024
CataractFundingGene TherapyMyopiaNewsletterPharmaRetina
ONL Leads Latest Ophthalmic Fundraising with $65M Series D Round
ONL Leads Latest Ophthalmic Fundraising with $65M Series D Round

ONL Therapeutics led recent ophthalmic fundraising efforts with a $65 million Series D round to continue advancing its small-molecule Fas inhibitor for retinal disease. Financing announced in the p...

7/23/2024
BiosimilarsCornealFundingGene TherapyMyopiaNewsletterPresbyopiaRetina
Beacon Leads Latest Ophthalmic Fundraising with $170 Million in Series B
Beacon Leads Latest Ophthalmic Fundraising with $170 Million in Series B

Beacon Therapeutics led recent ophthalmic fundraising efforts with $170 million in Series B funding to advance its candidates for retinal disease. Financing announced in the past four weeks totaled...

7/23/2024
BiosimilarsClinical TrialCornealDealsDry EyeEuropeGene TherapyGlaucomaIndiaIndustryMyopiaNewsletterRegulationRetina
July 2024 Ophthalmic News Briefs
July 2024 Ophthalmic News Briefs

Bausch + Lomb announced July 23 that it had acquired dry eye diagnostic company Trukera Medical from its private equity owner, AccelMed Partners, and other shareholders. No financial details were d...

7/19/2024
BreakingIndustryMyopia
Sydnexis Appoints Perry J. Sternberg as Chief Executive Officer
Sydnexis Appoints Perry J. Sternberg as Chief Executive Officer

Sydnexis, of Del Mar, California, announced July 16 that Perry J. Sternberg had been appointed chief executive officer and as a member of the board of directors. He will join the company on Aug. 5,...

6/28/2024
BreakingMyopiaRegulation
Vyluma Plans to Resubmit NDA for Low-Dose Atropine for Myopia after Meeting with US FDA
Vyluma Plans to Resubmit NDA for Low-Dose Atropine for Myopia after Meeting with US FDA

Vyluma announced June 18 that it had met with the US FDA’s Division of Ophthalmology to discuss resubmitting its new drug application (NDA) for lead compound NVK002, a low-dose formulation of atrop...

6/24/2024
CataractClinical TrialData SecurityDealsDiagnosticDry EyeGene TherapyGlaucomaIOLIndustryMyopiaNewsletterRefractiveRegulationRetinaSurgical
June 2024 Ophthalmic News Briefs
June 2024 Ophthalmic News Briefs

Japan’s Nidek announced June 3 that it had launched the RS-1 Glauvas OCT system. The device is CE marked as a Class IIa device. Nidek said the RS-1 Glauvas’ streamlined workflow and advanced analyt...

5/31/2024
BreakingClinical TrialEuropeMyopia
Dopavision Sees Positive Results in Trial of Photobiomodulation for Myopia
Dopavision Sees Positive Results in Trial of Photobiomodulation for Myopia

Germany’s Dopavision reported May 28 that its MyopiaX photobiomodulation system targeting myopia showed signals of clinical effect on the rate of progression at six months in a proof-of-concept tri...

5/31/2024
BreakingEuropeMyopiaRegulation
EU Accepts Vyluma’s Marketing Application for Low-Dose Atropine in Childhood Myopia
EU Accepts Vyluma’s Marketing Application for Low-Dose Atropine in Childhood Myopia

Vyluma reported May 29 that the European Medicines Agency had accepted its marketing application for lead compound NVK002, a low-dose formulation of atropine targeting childhood myopia. NVK002 is a...

3/21/2024
ChinaIndiaMeetingMyopiaNewsletter
2024 APAO Congress Brainstorms How to Expand Access to Eye Care; Companies Showcase Tech Boom
2024 APAO Congress Brainstorms How to Expand Access  to Eye Care; Companies Showcase Tech Boom

Nearly 7,800 delegates attended the 2024 congress of the Asia-Pacific Academy of Ophthalmology in southern Bali from Feb. 22-25. The 253 sessions and 120 exhibits spread across four floors in two n...

3/15/2024
BreakingMyopiaRefractiveRegulation
Santen Files for Marketing Approval in Japan for Atropine Drops to Delay Myopia
Santen Files for Marketing Approval in Japan for Atropine Drops to Delay Myopia

Santen Pharmaceutical announced Feb. 28 that it had filed for marketing approval in Japan of DE-127 (0.025% atropine sulfate hydrate eye drop), designed to slow the progression of myopia. The produ...

1/23/2024
DealsMyopiaNewsletterRefractive
Eyenovia Reacquires Rights to MicroPine in US, Canada from Bausch + Lomb
Eyenovia Reacquires Rights to MicroPine  in US, Canada from Bausch + Lomb

Eyenovia announced Jan. 16 that it had reacquired the rights to pediatric myopia candidate MicroPine in the US and Canada from Bausch + Lomb. The investigational formulation of atropine, intended f...

1/23/2024
CataractMyopiaNewsletterPharmaRegulation
US FDA PDUFA Target Action Dates for Ophthalmic Candidates, 2024
US FDA PDUFA Target Action Dates for Ophthalmic Candidates, 2024

The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic prescription and biologic drug candidates and those classified as drug/device combin...

1/19/2024
BreakingDealsMyopiaPharma
Eyenovia Reacquires Rights to MicroPine in US, Canada from Bausch + Lomb
Eyenovia Reacquires Rights to MicroPine in US, Canada from Bausch + Lomb

Eyenovia announced Jan. 16 that it had reacquired the rights to pediatric myopia candidate MicroPine in the US and Canada from Bausch + Lomb. The investigational formulation of atropine, intended f...

11/21/2023
AAOMeetingMyopiaNewsletterRefractiveSurgical
US Refractive Surgeons Grapple with Treatment Options for High Myopes
US Refractive Surgeons Grapple with Treatment Options for High Myopes

Surgeons attending the Refractive Subspecialty Day at the 2023 AAO meeting in San Francisco debated the ideal treatment options for patients with moderate to high myopia. Practices shared widely di...

8/22/2023
CornealEmergingMyopiaNewsletterRetina
Emerging Companies Pursuing Ophthalmic Indications, August 2023
Emerging Companies Pursuing Ophthalmic Indications, August 2023

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

Want to Read the Full Article?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more